Your session is about to expire
← Back to Search
Diagnostic Imaging with 64Cu-PSMA-I&T for Prostate Cancer
Study Summary
This trial evaluates a new imaging technique to detect recurrent prostate cancer after treatment.
- Prostate Cancer Metastasis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How widespread is the availability of this medical experiment?
"This clinical study has 5 participating sites, including Saint Louis University in Missouri and Washington University in Omaha. Furthermore, Nebraska Cancer Specialists is offering patient support in Houston, with additional locations available as well."
How perilous is 64Cu-PSMA-I&T for patient health when utilized in Diagnostic Imaging?
"Our Power team assesses the safety of Diagnostic Imaging with 64Cu-PSMA-I&T to be a 2 because, although Phase 2 indicates some evidence for safety, there is yet to be any proof of its efficacy."
Is there still room for participants in this research project?
"As reported on clinicaltrials.gov, the recruitment process for this particular trial has concluded. Initially posted December 1st 2022 and last updated December 7th 2022, it is no longer accepting any participants at this time; however, there are an abundance of other studies available now numbering 3601 in total."
Share this study with friends
Copy Link
Messenger